This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
by Indrajit Bandyopadhyay
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
by Harshit Gupta
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
by Indrajit Bandyopadhyay
OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.
Health Catalyst (HCAT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Health Catalyst (HCAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Q1 Earnings Meet Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
by Zacks Equity Research
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Beyond Tempus AI: 2 Health IT Stocks Poised for Growth in 2025
by Urmimala Biswas
AI-driven healthcare companies like Butterfly Network and Health Catalyst have all the qualities to emerge as the next big players.
Is the Options Market Predicting a Spike in Health Catalyst (HCAT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.
Compared to Estimates, Health Catalyst (HCAT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of -63.64% and 0.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Butterfly Network, Inc. (BFLY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Butterfly Network (BFLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About Health Catalyst (HCAT) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Health Catalyst (HCAT) Q3 Earnings Miss Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of -30% and 0.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 900% and 2.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Health Catalyst (HCAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Time to Play 5 Top-Ranked Stocks With Rising P/E?
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
Why Health Catalyst (HCAT) Might be Well Poised for a Surge
by Zacks Equity Research
Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.